Robotic secondary cytoreduction in recurrent ovarian cancer: a tailored approach for kidney transplant recipients
PDF
Cite
Share
Request
Video Commentary
E-PUB
8 December 2025

Robotic secondary cytoreduction in recurrent ovarian cancer: a tailored approach for kidney transplant recipients

Facts Views Vis ObGyn. Published online 8 December 2025.
1. Division of Gynaecology and Obstetrics, Catholic University of the Sacred Heart, Rome, Italy
2. Department of Women’s and Children’s Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
3. Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
4. Department of Women’s and Children’s Health Sciences, Complex Operative Unit General Pathological Anatomy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
No information available.
No information available
Received Date: 12.03.2025
Accepted Date: 26.07.2025
E-Pub Date: 08.12.2025
PDF
Cite
Share
Request

ABSTRACT

Click here to watch the video

Background

The rate of kidney transplantation has been steadily increasing worldwide, accompanied by significant improvements in post-transplant survival rates. However, transplant recipients have a higher incidence of malignancies compared with the general population, and their oncological management often poses unique challenges. In recent years, major advances in the treatment of ovarian cancer have expanded the therapeutic options available for recurrent disease. Two randomised trials have underscored the role of surgery in platinum-sensitive recurrent ovarian cancer while minimally invasive approaches have demonstrated reduced morbidity without compromising oncologic outcomes in carefully selected patients. For frail and immunosuppressed individuals, the minimally invasive approach may offer substantial advantages- including fewer wound complications, shorter hospitalisation, and earlier resumption of oral intake and immunosuppressive therapy. Despite these potential benefits, evidence regarding the feasibility and safety of minimally invasive secondary cytoreduction in kidney-transplanted patients remains limited.

Objectives

To demonstrate the feasibility and outcomes of robotic surgery in a platinum-sensitive ovarian cancer (OC) recurrence in a frail, kidney-transplant patient.

Participant

A woman in her 50s with a history of kidney transplantation presented with isolated pelvic high-grade serous OC recurrence. Positron emission tomography scan revealed a 15 mm solid lesion with increased uptake infiltrating the rectum.

Intervention

A robot-assisted rectal resection was performed using the Da Vinci Xi Surgical System. The approach included four 8 mm robotic trocars: trans umbilical optical port, right and left iliac fossa, suprapubic region, and one 10 mm laparoscopic port at the left Palmer’s point. Colorectal anastomosis was completed using the Ethicon Endo-Surgery 60 mm stapler by a specialised peritoneal and retroperitoneal team.

Conclusions

R0 resection was achieved with no complications or delays in immunosuppressive therapy resumption; final histology confirmed rectal involvement, and adjuvant chemotherapy was promptly initiated. At the two-year follow-up, the patient was disease-free.

What is New?

This case supports minimally invasive surgery as a valid approach in selected, frail, immunosuppressed patients with isolated OC recurrence.

Keywords:
Feasibility, kidney transplantation, ovarian cancer, robotic-assisted, robotic surgery

Video 1. Robotic secondary cytoreduction for platinum-sensitive recurrent ovarian cancer in a kidney-transplant patient. The video demonstrates a minimally invasive rectal resection in a frail, immunosuppressed patient using the Da Vinci Xi Surgical System. This tailored approach allowed for complete cytoreduction (R0) without delaying the resumption of immunosuppressive therapy. The case supports the feasibility of robotic surgery in selected post-transplant oncologic cases.1-5

Acknowledgements

The authors wish to thank the surgical and nursing staff of the Gynecologic Oncology Unit at Fondazione Policlinico Universitario A. Gemelli IRCCS for their valuable collaboration and assistance during the procedures and video preparation.

Contributors

Surgical and Medical Practices: S.A.R., C.C., L.P., C.L., A.S., G.S., V.G.,  Concept: S.A.R., R.O., C.C., S.A., L.P., C.L., F.S., A.S., A.F., G.S., V.G., Design: S.A.R., R.O., C.C., S.A., L.P., C.L., F.S., A.S., A.F., G.S., V.G., Data Collection or Processing: S.A.R., R.O., C.C., L.P., C.L., F.S., A.S., V.G., Literature Search: S.A.R., R.O., C.C., S.A., L.P., Writing: S.A.R., C.C., A.F., G.S., V.G.
Funding: The authors declared that this study received no financial support.
Competing interests: No conflict of interest was declared by the authors.
Ethical approval: Not required.
Informed consent: Informed consent was not required for this study, as the report is fully anonymised and contains no identifiable patient information.
Data sharing: The data supporting the findings of this study are available from the corresponding author upon reasonable request.
Transparency: The authors affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Suplementary Materials